Karuna Therapeutics

Karuna Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing transformative medicines for neuropsychiatric disorders. The company was acquired by Bristol-Myers Squibb in March 2024.

Overview

Founded in 2009 as Karuna Pharmaceuticals, the company developed KarXT (xanomeline-trospium), a novel muscarinic receptor agonist with potential applications in schizophrenia and psychosis associated with Alzheimer's disease["@karuna"].

Funding

Karuna Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing transformative medicines for neuropsychiatric disorders. The company was acquired by Bristol-Myers Squibb in March 2024.

Overview

Founded in 2009 as Karuna Pharmaceuticals, the company developed KarXT (xanomeline-trospium), a novel muscarinic receptor agonist with potential applications in schizophrenia and psychosis associated with Alzheimer's disease["@karuna"].

Funding

• IPO: 2019 (NASDAQ: KRTX)
• Acquired: 2024 by Bristol-Myers Squibb ($14B)
• Prior Funding: Series A-C

Company History

• Founded: 2009
• Headquarters: Boston, Massachusetts
• Founded By: Dr. Jeffrey L. Apter, Dr. John R. M. Kem
• Acquired: Bristol-Myers Squibb (March 2024)
• Employees: Approximately 300 at acquisition

History and Development

Early Development (2009-2018)

Clinical Development (2018-2023)

• 2018: Initiated Phase 1 trials for KarXT
• 2019: Completed Phase 1 showing safety and tolerability
• 2021: Started EMERGENT Phase 3 program in schizophrenia
• 2022: Reported positive Phase 2 results (EMERGENT-1)
• 2023: Reported positive Phase 3 results (EMERGENT-2/3/4)

Acquisition by Bristol-Myers Squibb

• Announcement: December 2023
• Closing: March 2024
• Deal Value: Approximately $14.6 billion USD ($330 per share)
• Strategic Rationale: BMS sought to strengthen its neuroscience portfolio and gain access to novel neuropsychiatric treatments[@karunaa]

Key Pipeline: KarXT (Xanomeline-Trospium)

Mechanism of Action

KarXT is a novel muscarinic receptor agonist that selectively targets M1 and M4 muscarinic acetylcholine receptors while avoiding D2 dopamine receptor blockade. This represents a fundamentally different mechanism from current antipsychotics[@karxt]:

• Xanomeline: Muscarinic agonist (M1/M4 selective)
• Trospium: Peripheral muscarinic antagonist (limits side effects)
• Net Effect: Central nervous system muscarinic activation without peripheral toxicity

Why Muscarinic Agonism for Psychosis?

The cholinergic hypothesis of psychosis suggests that:

• M1 receptor activation may improve cognitive function
• M4 receptor activation may reduce psychotic symptoms
• Muscarinic dysfunction contributes to treatment-resistant symptoms

Clinical Development

| Trial | Indication | Stage | Results |
|-------|------------|-------|---------|
| EMERGENT-1 | Schizophrenia | Phase 2 | Positive (2022) |
| EMERGENT-2 | Schizophrenia | Phase 3 | Positive (2023) |
| EMERGENT-3 | Schizophrenia | Phase 3 | Positive (2023) |
| EMERGENT-4 | Schizophrenia | Phase 3 | Positive (2023) |
| ADEPT-1 | Alzheimer's psychosis | Phase 3 | Ongoing |
| ADEPT-2 | Alzheimer's psychosis | Phase 3 | Ongoing |
| ARISE | Schizophrenia (adjunct) | Phase 3 | Positive (2024) |

FDA Approval

• Brand Name: COBENFY
• Indication: Schizophrenia in adults
• Approval Date: October 2024
• Significance: First new mechanism for schizophrenia in decades[@cobenfy]

Science and Technology

Muscarinic Receptor Biology

• Nicotinic: Ligand-gated ion channels
• Muscarinic: G protein-coupled receptors (GPCRs)

• M1: Found in cortex and hippocampus; important for cognition
• M4: Found in striatum; may reduce psychotic symptoms

Combination Drug Design

• Xanomeline crosses the blood-brain barrier and activates CNS muscarinic receptors
• Trospium does NOT cross the BBB but blocks peripheral muscarinic side effects
• This maximizes CNS benefit while minimizing peripheral toxicity

Financial Highlights

• Pre-acquisition market cap: Approximately $12 billion USD
• Acquisition price: $14.6 billion USD ($330/share)
• Key investors: ARCH Venture Partners, Andreessen Horowitz, Perceptive Advisors
• R&D spending: Approximately $200 million annually

Neurological Relevance

The muscarinic receptor approach represents a paradigm shift in psychosis treatment[@muscarinic2022]:

Addresses Dopamine Dysfunction Through Cholinergic Modulation

• Targets underlying cholinergic dysfunction in psychosis
• May improve cognitive symptoms beyond positive symptoms

Potential Benefits for Multiple Indications

• Schizophrenia (primary)
• [Alzheimer](/diseases/alzheimers-disease)'s disease psychosis
• [Parkinson](/diseases/parkinsons-disease)'s disease psychosis
• Bipolar disorder

Advantages Over Current Treatments

• No extrapyramidal symptoms (EPS)
• No hyperprolactinemia
• Reduced metabolic side effects
• Potential cognitive improvement

Addresses Treatment-Resistant Schizophrenia

• Mechanism distinct from D2 blockade
• May benefit patients refractory to current treatments
• [Schizophrenia](/diseases/schizophrenia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Psychosis](/therapeutics/nelotanserin-parkinsons-psychosis)
• [Parkinson's Disease](/genes/ar)
• [Bipolar Disorder](/genes/ar)
• [Muscarinic Signaling](/genes/ar)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Cholinergic Signaling](/genes/gnal)
• [Bristol-Myers Squibb](/companies/bristol-myers)
• COBENFY
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References